Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Gyroscope Therapeutics

Explore full profile

Developing one-time gene therapies for retinal diseases

London, United KingdomFounded 2016Biotech & Life Sciences
Valuation $500M–1B Last recorded · 2021
Revenue <$1M Latest reported FY
Headcount <100 Current team size
Total funding $100–500M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Gyroscope Therapeutics and the history behind them.

About Gyroscope Therapeutics

Gyroscope Therapeutics is a pioneering biotechnology company focused on developing innovative gene therapies and surgical delivery devices to treat eye diseases, particularly those leading to blindness. The company operates in the ophthalmology market, targeting conditions such as age-related macular degeneration (AMD), a leading cause of irreversible blindness in the elderly. Gyroscope collaborates with academic institutions, pharmaceutical, and biotech companies to advance clinical research and bring cutting-edge treatments to market. The business model revolves around the discovery, development, and commercialization of one-time gene therapies, which offer a potentially curative approach to eye diseases. Revenue is generated through partnerships, licensing agreements, and the eventual sale of approved therapies. Gyroscope's commitment to preserving sight and combating blindness positions it as a key player in the ophthalmology sector.

Source: Dealroom company data

At a glance

Founded
2016
Headquarters
London, United Kingdom
Sector
Biotech & Life Sciences
Power Law
Unicorn$1–10B valuation tier

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom
Market map
Market map Longevity Europe

Investors

8 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A2 investors entered at this stage

  • Syncona
  • Cambridge Innovation Capital

Series B and later6 investors entered at this stage

  • Forbion Capital Partners
  • Sofinnova Investments
  • T. Rowe Price
  • Shanghai Fosun Pharmaceutical
  • Tetragon Financial Group
  • Sanofi

Talent

Book a demo to see the people
Team profiled 11 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 4 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇬🇧 United Kingdom · London HQ
Book a demo for the full country breakdown

Patents

Estimated portfolio value
$46M

21 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Gyroscope Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Gyroscope Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles